Tech Company Financing Transactions
SeQure Dx Funding Round
SeQure Dx closed a $17.5 million Series A funding round on 8/4/2021. Investors included Mass General Brigham Innovation, RiverVest Venture Partners and Alexandria Venture Investments.
Transaction Overview
Company Name
Announced On
8/4/2021
Transaction Type
Venture Equity
Amount
$17,500,000
Round
Series A
Investors
Proceeds Purpose
Funds will be used for initial company development leading to establishment of a full-service laboratory providing off-target gene-editing analysis for use in drug development, clinical trials and ultimately patient evaluation prior to therapy.
Company Information
Company Status
Private & Independent
Industry
Healthcare IT
Mailing Address
1440 Main St. 320
Waltham, MA 02451
USA
Waltham, MA 02451
USA
Phone
Undisclosed
Website
Email Address
Overview
SeQure Dx, Inc. is applying state of the art genomics technologies for gene editor target profiling to advance discovery, clinical development, and diagnostic solutions. This information provides gene editing therapeutics developers, physicians and patients with the confidence needed to ensure safe and effective gene therapies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Ellen Sheets
Chief Scientific Officer
Douglas Smith
VP - Administration
Daniel Davis
VP - Bus. Development
Marc Rubenfield
Browse more venture capital transactions:
Prev: 8/4/2021: Ahana venture capital transaction
Next: 8/5/2021: HeyRenee venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to document all VC transactions involving tech companies. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs